Trust Co. of Toledo NA OH Has $1.56 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Trust Co. of Toledo NA OH trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.7% during the second quarter, Holdings Channel reports. The firm owned 14,050 shares of the biopharmaceutical company’s stock after selling 100 shares during the period. Trust Co. of Toledo NA OH’s holdings in Gilead Sciences were worth $1,558,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Brucke Financial Inc. boosted its holdings in Gilead Sciences by 57.8% during the second quarter. Brucke Financial Inc. now owns 3,611 shares of the biopharmaceutical company’s stock valued at $400,000 after purchasing an additional 1,322 shares in the last quarter. PDS Planning Inc boosted its holdings in Gilead Sciences by 11.4% during the second quarter. PDS Planning Inc now owns 5,790 shares of the biopharmaceutical company’s stock valued at $642,000 after purchasing an additional 592 shares in the last quarter. Blue Trust Inc. boosted its holdings in Gilead Sciences by 12.5% during the second quarter. Blue Trust Inc. now owns 4,497 shares of the biopharmaceutical company’s stock valued at $499,000 after purchasing an additional 499 shares in the last quarter. Costello Asset Management INC boosted its holdings in Gilead Sciences by 244.1% during the second quarter. Costello Asset Management INC now owns 320 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 227 shares in the last quarter. Finally, Monument Capital Management boosted its holdings in Gilead Sciences by 13.4% during the second quarter. Monument Capital Management now owns 9,242 shares of the biopharmaceutical company’s stock valued at $1,025,000 after purchasing an additional 1,092 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. UBS Group lifted their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research note on Friday, August 8th. Cantor Fitzgerald lifted their target price on shares of Gilead Sciences from $129.00 to $135.00 and gave the company an “overweight” rating in a research note on Thursday. Needham & Company LLC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price for the company in a research note on Friday, July 25th. Rothschild & Co Redburn lifted their target price on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Finally, Daiwa America upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $118.08.

Gilead Sciences Price Performance

Shares of GILD stock opened at $117.18 on Friday. Gilead Sciences, Inc. has a 12-month low of $84.17 and a 12-month high of $121.83. The firm has a market capitalization of $145.40 billion, a price-to-earnings ratio of 23.34, a price-to-earnings-growth ratio of 0.79 and a beta of 0.34. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The firm has a fifty day moving average of $114.65 and a 200-day moving average of $110.25.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the previous year, the business earned $2.01 EPS. The firm’s revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were issued a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. Gilead Sciences’s payout ratio is 62.95%.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction on Monday, July 28th. The shares were sold at an average price of $113.94, for a total value of $1,139,400.00. Following the completion of the transaction, the chief executive officer owned 605,725 shares of the company’s stock, valued at $69,016,306.50. The trade was a 1.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the transaction, the insider directly owned 114,168 shares of the company’s stock, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock worth $9,402,130 over the last quarter. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.